2023
Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Real-World Treatment Patterns and Overall Survival Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Claims Data. Blood 2023, 142: 2428. DOI: 10.1182/blood-2023-178755.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAcute myeloid leukemiaNon-transplant recipientsR AML patientsIndex dateAML patientsOverall survivalTreatment patternsND patientsIntensive chemotherapyAML diagnosisR patientsDiagnosis codesTransplant recipientsOlder patientsSupportive careIntensive therapyContinuous enrollmentNovel therapiesLarge US administrative claims databaseUnmet needRefractory acute myeloid leukemia patientsReal-world treatment patternsUS administrative claims databaseAcute myeloid leukemia patients
2019
Healthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML